And so, one other working week will quickly draw to a detailed. Already, you say? Nicely, there’s a vacation arising on this facet of the pond. So we’re fortunately daydreaming about weekend plans. Our agenda is unsure. We do plan, nevertheless, to hold with all of our quick individuals, nosh on some favourite meals, and, sure, maintain one more itemizing get together. This time round, the rotation will possible embrace this, this, this, this and this. And what about you? There could also be no higher time to benefit from the nice outdoor, a perennial aspiration of ours. In spite of everything, climbing trails, boardwalks, and nation roads are beckoning. You would additionally take a second to twist up with a great e book or look in on somebody particular. Otherwise you would possibly need to merely plan the remainder of your life. Nicely, no matter you do, have a grand time. However be protected. Get pleasure from, and see you on Monday. …
A memo that purports to summarize a gathering held by members of a number one biotech commerce group suggests deep concern about well being secretary Robert F. Kennedy Jr.’s stance on vaccines, and describes him as a “direct menace to public well being,” STAT writes. The four-page doc purportedly particulars matters of dialog at an April 3 assembly of a vaccine coverage committee of the commerce group BIO, during which attendees mentioned anxieties about Kennedy’s positions on vaccines and methods to have interaction with extra conservative influencers. The doc additionally consists of an obvious quote from somebody in attendance: “it’s time to go to The Hill and foyer that it’s time for RFK Jr to go.” BIO mentioned the memo was not produced by the group and doesn’t mirror its plans. “Now we have by no means seen or heard of this doc and it actually doesn’t precisely signify the spirit, technique, or mission of BIO’s work,” spokesperson Scott Frotman mentioned in a press release.
Novartis’s drug Cosentyx failed in a late-stage examine of sufferers affected by irritation of their blood vessels, a blow to its efforts to search out new makes use of for the blockbuster drugs, Bloomberg Information tells us. The remedy, already one among Novartis’s high sellers, didn’t exhibit statistically vital enchancment in grownup sufferers affected by big cell arteritis, an ailment that may trigger lack of imaginative and prescient and life-threatening aneurysms. The drug was in contrast with placebo, with all trial contributors additionally getting a steroid. Cosentyx is already used for treating illnesses together with psoriasis and the drug is predicted to generate about $7 billion in gross sales this 12 months, in response to knowledge compiled by Bloomberg. Novartis chief govt officer Vas Narasimhan just lately mentioned that if Cosentyx proved profitable in treating big cell arteritis, it might herald one other $500 million in income yearly. The corporate had listed the trial as one among its largest pipeline occasions in 2025. It mentioned it plans a full analysis of the trial knowledge and can share extra outcomes at a later date.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
